Autolus Therapeutics

Patent cliffs & loss of exclusivity

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

Company

AngelList URLhttps://angel.co/company/autolus
Legal NameAutolus Therapeutics plc
Company Operating StatusActive
Contact Page URLhttps://www.autolus.com/contact-us/
Crunchbase URLhttps://www.crunchbase.com/organization/autolus-limited
Email format{f}.{last}
Full Address191 Wood Lane White City London W12 7FP
Legal Entity Identifier549300C0KZP8EYROLL02

1 upcoming patent cliff

DrugIngredientTypeCliff
  1. AucatzylObecabtagene autoleucelBiologicNov 2036

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Autolus Therapeutics — patent cliffs & loss of exclusivity | CliffBio